Phosphoinositide 3'-Kinase Inhibition in Chronic Lymphocytic Leukemia

Hematology/Oncology Clinics of North America

Volumn 27, Issue 2, 2013, Pages 329-339

  Davids, Matthew S ^a   Brown, Jennifer R ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

B cell receptor; Lymphoid leukemia; Phosphoinositide 3' kinase; Signaling therapies

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; BENDAMUSTINE; FLUDARABINE; IDELALISIB; LENALIDOMIDE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE; PROTEIN KINASE LYN; PROTEIN KINASE ZAP 70; XL 147;

APOPTOSIS; AUTOPHOSPHORYLATION; CELL FUNCTION; CELL SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL (TOPIC); ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; LYMPHOCYTOSIS; MOLECULAR INTERACTION; NEUTROPENIA; PHASE 1 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRIORITY JOURNAL; RASH; REVIEW; THROMBOCYTOPENIA; TREATMENT RESPONSE; UPREGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS; ENZYME INHIBITORS; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; PHOSPHATIDYLINOSITOL 3-KINASES; PROGNOSIS; TOR SERINE-THREONINE KINASES; TREATMENT OUTCOME;

EID: 84875774940     PISSN: 08898588     EISSN: 15581977     Source Type: Journal    
DOI: 10.1016/j.hoc.2012.12.002     Document Type: Review

References (48)

1. Chiorazzi N., Rai K.R., Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med 2005, 352(8):804-815.
2. Burger J.A., Ghia P., Rosenwald A., et al. The microenvironment in mature B-cell malignancies: a target for new treatment strategies. Blood 2009, 114(16):3367-3375.
3. Stevenson F.K., Caligaris-Cappio F. Chronic lymphocytic leukemia: revelations from the B-cell receptor. Blood 2004, 103(12):4389-4395.
4. Friedberg J.W., Sharman J., Sweetenham J., et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 2010, 115(13):2578-2585.
5. Zent C.S., LaPlant B.R., Johnston P.B., et al. The treatment of recurrent/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) with everolimus results in clinical responses and mobilization of CLL cells into the circulation. Cancer 2010, 116(9):2201-2207.
6. Lannutti B.J., Meadows S.A., Herman S.E., et al. CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood 2011, 117(2):591-594.
7. Honigberg L.A., Smith A.M., Sirisawad M., et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci U S A 2010, 107(29):13075-13080.
8. Hawkins P.T., Anderson K.E., Davidson K., et al. Signalling through Class I PI3Ks in mammalian cells. Biochem Soc Trans 2006, 34(Pt 5):647-662.
9. Vanhaesebroeck B., Ali K., Bilancio A., et al. Signalling by PI3K isoforms: insights from gene-targeted mice. Trends Biochem Sci 2005, 30(4):194-204.
10. Wang L., Lawrence M.S., Wan Y., et al. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med 2011, 365(26):2497-2506.
11. Brown J.R., Hanna M., Tesar B., et al. Integrative genomic analysis implicates gain of PIK3CA at 3q26 and MYC at 8q24 in chronic lymphocytic leukemia. Clin Cancer Res 2012, 18(14):3791-3802.
12. Herman S.E., Gordon A.L., Wagner A.J., et al. Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. Blood 2010, 116(12):2078-2088.
13. Monroe J.G. ITAM-mediated tonic signalling through pre-BCR and BCR complexes. Nat Rev Immunol 2006, 6(4):283-294.
14. Reth M. Antigen receptors on B lymphocytes. Annu Rev Immunol 1992, 10:97-121.
15. Koyasu S. The role of PI3K in immune cells. Nat Immunol 2003, 4(4):313-319.
16. Chantry D., Vojtek A., Kashishian A., et al. p110δ, a novel phosphatidylinositol 3-kinase catalytic subunit that associates with p85 and is expressed predominantly in leukocytes. J Biol Chem 1997, 272(31):19236-19241.
17. So L., Fruman D.A. PI3K signalling in B- and T-lymphocytes: new developments and therapeutic advances. Biochem J 2012, 442(3):465-481.
18. Shinohara H., Kurosaki T. Comprehending the complex connection between PKCbeta, TAK1, and IKK in BCR signaling. Immunol Rev 2009, 232(1):300-318.
19. Uriarte S.M., Joshi-Barve S., Song Z., et al. Akt inhibition upregulates FasL, downregulates c-FLIPs and induces caspase-8-dependent cell death in Jurkat T lymphocytes. Cell Death Differ 2005, 12(3):233-242.
20. She Q.B., Solit D.B., Ye Q., et al. The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells. Cancer Cell 2005, 8(4):287-297.
21. Hoellenriegel J., Meadows S.A., Sivina M., et al. The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood 2011, 118(13):3603-3612.
22. Davids M.S., Deng J., Wiestner A., et al. Decreased mitochondrial apoptotic priming underlies stroma-mediated treatment resistance in chronic lymphocytic leukemia. Blood 2012, 120:3501-3509.
23. Vanhaesebroeck B., Welham M.J., Kotani K., et al. P110delta, a novel phosphoinositide 3-kinase in leukocytes. Proc Natl Acad Sci U S A 1997, 94(9):4330-4335.
24. Niedermeier M., Hennessy B.T., Knight Z.A., et al. Isoform-selective phosphoinositide 3'-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach. Blood 2009, 113(22):5549-5557.
25. Herman S.E., Lapalombella R., Gordon A.L., et al. The role of phosphatidylinositol 3-kinase-delta in the immunomodulatory effects of lenalidomide in chronic lymphocytic leukemia. Blood 2011, 117(16):4323-4327.
26. Lee Y.K., Shanafelt T.D., Bone N.D., et al. VEGF receptors on chronic lymphocytic leukemia (CLL) B cells interact with STAT 1 and 3: implication for apoptosis resistance. Leukemia 2005, 19(4):513-523.
27. Konig A., Menzel T., Lynen S., et al. Basic fibroblast growth factor (bFGF) upregulates the expression of bcl-2 in B cell chronic lymphocytic leukemia cell lines resulting in delaying apoptosis. Leukemia 1997, 11(2):258-265.
28. Furman RR, Byrd JC, Brown JR, et al. CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110d demonstrates clinical activity and pharmacodynamic effects in patients with relapsed or refractory chronic lymphocytic leukemia. Blood (ASH Annual Meeting Abstracts), November 2010;116:55.
29. Hallek M., Cheson B.D., Catovsky D., et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008, 111(12):5446-5456.
30. Sharman J, de Vos S, Leonard J, et al. A phase 1 study of the selective PI3K inhibitor CAL-101 (GS-1101) in combination with rituximab and/or bendamustine in patients with relapsed or refractory CLL. Blood (ASH Annual Meeting Abstracts), November 2011;118:1787.
31. Luo J., Manning B.D., Cantley L.C. Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell 2003, 4(4):257-262.
32. Edelman G, Bedell G, Shapiro SS, et al. A phase I dose-escalation study of XL147 (SAR245408), a PI3K inhibitor administered orally to patients with advanced malignancies. J Clin Oncol (ASCO Annual Meeting Abstracts), 2010;28:15s:3004.
33. Martin A.L., Schwartz M.D., Jameson S.C., et al. Selective regulation of CD8 effector T cell migration by the p110 gamma isoform of phosphatidylinositol 3-kinase. J Immunol 2008, 180(4):2081-2088.
34. Brown J.R., Davids M.S., Rodon J., et al. Phase I trial of SAR245408 (S08), a pan-PI3K inhibitor, in patients with CLL and lymphoma November 2011, Blood (ASH Annual Meeting Abstracts), 118:2683.
35. Drakos E., Rassidakis G.Z., Medeiros L.J. Mammalian target of rapamycin (mTOR) pathway signalling in lymphomas. Expert Rev Mol Med 2008, 10:e4.
36. Papadopoulos K, Abrisqueta P, Chambers G, et al. A phase I dose escalation expansion cohort study of the safety, pharmacokinetics and pharmacodynamics of SAR245409 (S09), an orally administered PI3K/mTOR inhibitor, in patients with lymphoma. Blood (ASH Annual Meeting Abstracts), November 2011;118:1608.
37. Lorusso P, Markman J, Tabernero R, et al. A phase I dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics of XL765, a PI3K/TORC1/TORC2 inhibitor administered orally to patients (pts) with advanced solid tumors. J Clin Oncol (ASCO Annual Meeting Abstracts), 2009;27:15s:3502.
38. Wiestner A., Rosenwald A., Barry T.S., et al. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood 2003, 101(12):4944-4951.
39. Richardson S.J., Matthews C., Catherwood M.A., et al. ZAP-70 expression is associated with enhanced ability to respond to migratory and survival signals in B-cell chronic lymphocytic leukemia (B-CLL). Blood 2006, 107(9):3584-3592.
40. Hamblin T.J., Davis Z., Gardiner A., et al. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999, 94(6):1848-1854.
41. Guarini A., Chiaretti S., Tavolaro S., et al. BCR ligation induced by IgM stimulation results in gene expression and functional changes only in IgV H unmutated chronic lymphocytic leukemia (CLL) cells. Blood 2008, 112(3):782-792.
42. Coscia M., Pantaleoni F., Riganti C., et al. IGHV unmutated CLL B cells are more prone to spontaneous apoptosis and subject to environmental prosurvival signals than mutated CLL B cells. Leukemia 2011, 25(5):828-837.
43. Schall T.J., Bacon K., Camp R.D., et al. Human macrophage inflammatory protein alpha (MIP-1 alpha) and MIP-1 beta chemokines attract distinct populations of lymphocytes. J Exp Med 1993, 177(6):1821-1826.
44. Burger J.A., Quiroga M.P., Hartmann E., et al. High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation. Blood 2009, 113(13):3050-3058.
45. Herishanu Y., Perez-Galan P., Liu D., et al. The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood 2011, 117(2):563-574.
46. Puente X.S., Pinyol M., Quesada V., et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 2011, 475(7354):101-105.
47. Borchmann P., Eichhorst B., Hellmann M., et al. Dtsch Med Wochenschr 2008, 133(25-26):1400-1404. [in German].
48. Cheson B.D., Byrd J.C., Rai K.R., et al. Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia. J Clin Oncol 2012, 30(23):2820-2822.